Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)


Agarwal N., McQuarrie K., Bjartell A., Chowdhury S., Gomes A. J. P. D. S. , Chung B. H. , et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30

  • Cilt numarası: 30
  • Basıldığı Şehir: Barcelona
  • Basıldığı Ülke: İspanya